Literature DB >> 1548529

Reassessment of patient response to monoclonal antibody 3F8.

N V Cheung, H Lazarus, F D Miraldi, N A Berger, C R Abramowsky, U M Saarinen, T Spitzer, S E Strandjord, P F Coccia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1548529     DOI： 10.1200/JCO.1992.10.4.671

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial.

Authors:  S C Grant; L Kostakoglu; M G Kris; S D Yeh; S M Larson; R D Finn; H F Oettgen; N V Cheung
Journal:  Eur J Nucl Med       Date:  1996-02

Review 2.  GD2-targeted immunotherapy and radioimmunotherapy.

Authors:  Konstantin Dobrenkov; Nai-Kong V Cheung
Journal:  Semin Oncol       Date:  2014-07-21       Impact factor: 4.929

Review 3.  Monoclonal antibody-based therapy for neuroblastoma.

Authors:  N K Cheung
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

4.  Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.

Authors:  M M Uttenreuther-Fischer; C S Huang; R A Reisfeld; A L Yu
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

5.  Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.

Authors:  M M Uttenreuther-Fischer; C S Huang; A L Yu
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.